During the corresponding time, Agios Pharmaceuticals Inc recorded a revenue increase by 137.75 % year on year, sequentially revenue grew by 3.9 %. While revenue at the Agios Pharmaceuticals Inc 's corporate clients
Agios Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
Customers are subject to various federal and state health care laws and regulations affecting business and financial arrangements. These include the federal Anti-Kickback Statute, federal civil and criminal false claims laws such as the False Claims Act, HIPAA and its amendments, the federal false statements statute, the Foreign Corrupt Practices Act, and the federal Physician Payments Sunshine Act under the Affordable Care Act, along with analogous state and foreign laws. These regulations govern interactions involving federal health care programs like Medicare and Medicaid and also apply to health care items or services reimbursed by non-government third-party payors, including private insurers. Relevant market segments include manufacturers of drugs, devices, biologics, and medical supplies, as well as physicians, other healthcare providers, and teaching hospitals.
In a significant move to enhance its market presence and address the needs of patients with rare blood clotting disorders, Agios Pharmaceuticals Inc. (NASDAQ: AGIO) announced a strategic partnership with Avanzanite. This collaboration aims to facilitate the introduction of PYRUKYND, a key therapeutic product, across Europe. The initiative not only solidifies Agios s commitment to advancing patient care but also positions the company favorably within the competitive pharmaceutical landscape.As of this writing, Agios Pharmaceuticals Inc. shares are trading at $34.51, reflecting a robust performance of 1.56% over the current month, outpacing market benchmarks. Year-to-date, AGIO has shown impressive gains, exce...
Groundbreaking Phase 3 ENERGIZE Study Shows Promise for Non-Transfusion-Dependent Thalassemia Treatment: A Comprehensive Assessment CSIMarket.com is pleased to present an intriguing breakthrough in the treatment of non-transfusion-dependent alpha- and beta-thalassemia, as unveiled by Agios Pharmaceuticals. At the 2024 European Hematology Association (EHA) Hybrid Congress, Agios presented the groundbreaking results of its Phase 3 ENERGIZE study. This study marks a pivotal moment in addressing a significant unmet need for patients suffering from these thalassemia subtypes. The findings offer a new, efficacious oral treatment option in the form of Mitapivat, which demonstrated a statistically significant inc...
Agios Pharmaceuticals Achieves Major Milestones in Thalassemia and Sickle Cell Disease ResearchAgios Pharmaceuticals, renowned for its innovative therapies targeting rare genetic diseases, has marked significant advancements in the treatment landscape for patients with thalassemia and sickle cell disease. The company recently announced the success of its Phase 3 ENERGIZE-T study for Mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia, achieving both the primary and all key secondary endpoints. This milestone follows closely on the heels of their prior success with the Phase 3 ENERGIZE study in non-transfusion-dependent adults with the same conditions. Additionally, the company reported...
Biopharmaceutical company Agios has made a major breakthrough in the treatment of sickle cell disease, it revealed at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Presenting the positive results garnered from the phase 2 portion of the RISE UP Pivotal study, Agios showcased an innovative approach to combatting a historically stubborn disease. The RISE UP study, undertaken in a multi-centered, randomized, and double-blinded setting, aimed to address the trial of Agios’s new drug targeting the root cause of sickle cell disease. The condition, a group of inherited red blood cell disorders, has long been a medical puzzle, with no effective treatment except bone marrow ...
In a groundbreaking development, Agios Pharmaceuticals has recently announced the successful clinical proof-of-concept in a Phase 2a trial of their novel drug, AG-946, for the treatment of anemia in lower-risk Myelodysplastic Syndromes (MDS). This game-changing advancement not only addresses a significant unmet medical need but also showcases remarkable progress in enhancing the quality of life for patients suffering from this debilitating condition. AG-946 in Focus: Lower-risk MDS, characterized by an impaired production of healthy blood cells, has long posed challenges in anemia treatment. Agios AG-946 comes as a beacon of hope through its unique mechanism of action that targets the unde...
Agios Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
Customers are subject to various federal and state health care laws and regulations affecting business and financial arrangements. These include the federal Anti-Kickback Statute, federal civil and criminal false claims laws such as the False Claims Act, HIPAA and its amendments, the federal false statements statute, the Foreign Corrupt Practices Act, and the federal Physician Payments Sunshine Act under the Affordable Care Act, along with analogous state and foreign laws. These regulations govern interactions involving federal health care programs like Medicare and Medicaid and also apply to health care items or services reimbursed by non-government third-party payors, including private insurers. Relevant market segments include manufacturers of drugs, devices, biologics, and medical supplies, as well as physicians, other healthcare providers, and teaching hospitals.
Sources:
Agios Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Agios Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Agios Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
46.36 %